RenovoRx Inc. Common Stock (RNXT)

FairStock Score: 35/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a value investor, I look for durable earnings power bought at a sensible price. RenovoRx does not offer that today. It is a clinical-stage biotech with 17 employees, developing RenovoCath-delivered gemcitabine for locally advanced pancreatic cancer. The financials show only one clear positive: revenue direction. Revenue rose from $422,000 in fiscal Q2 2025 to $909,000 in fiscal Q2 2026, and later filings show $266,000 in fiscal Q3 2025, $563,000 in fiscal Q1 2026, and $909,000 in fiscal Q2 2026. But the company lost $2.9M in fiscal Q2 2026 and $11.2M in FY2025, after $8.8M in FY2024 and $10.2M in FY2023. Trailing free cash flow is -$11.9M, a -23.0% FCF yield against the $51.9M market cap as of the 2026-10-13 close. As of that close, FairStock calculations show P/E -3.71, P/B 5.75, ROE -125.23%, ROCE -64.90%, and a FairStock Score of 35/100. Those numbers mean there is no earnings-based valuation support. The Piotroski F-Score of 2/9 confirms weak fundamental momentum. The Altman Z-Score of 4.26 and debt-to-equity of 0.04 are relative positives, so leverage is not the immediate issue. But the business is cash-consuming and its value depends almost entirely on Phase III success. Without profits, a moat is unproven. At $1.15, investors are paying for future hope rather than current value. I would want proof of commercial traction, controlled cash burn, and trial progress before calling it cheap.

In plain English: RenovoRx is a small company testing a cancer treatment delivered by a special catheter. It brings in only a little money and loses much more than it earns, with no yearly profit in the past four years. At $1.15 a share, the price looks expensive compared with its tiny sales and losses, even though it has very little debt.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer